Nootropics Index - Save on smarter supplements
Nootropics>Choline donors & cholinergic compounds>Huperzine A
Choline donors & cholinergic compounds

Huperzine A

Huperzine A (Huperzia serrata alkaloid)

Huperzine A is a potent isolated alkaloid and acetylcholinesterase inhibitor, usually sourced from Huperzia serrata or sold as a standardized 1% ingredient. Human research is concentrated in Alzheimer disease and mild cognitive impairment contexts, with mixed results and important study-quality limits; that is not enough to support healthy-adult nootropic claims. Current product finder data show 17 visible products across 3 vendors, including 200 mcg capsules and multiple 1% powders. Compare stated active amount, assay/COA documentation, capsule versus powder handling, and form-specific price before comparing offers.

Focus SupportAttention SupportMemory SupportCholinergicAcetylcholine SupportAcetylcholinesterase RelatedStandardized Extract
Updated August 2026/6 min read/9 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
01

What is it?

A potent cholinergic compound, not a simple herb

2

Huperzine A is an isolated alkaloid usually associated with Huperzia serrata. For supplement shoppers, the important point is potency: active amounts are measured in micrograms, and many powders are standardized to 1% huperzine A rather than being pure active compound.

Clinical research is not the same as healthy nootropic proof

4

The human literature is mostly in Alzheimer's disease or mild cognitive impairment contexts. Some reviews report cognitive-scale signals, but Cochrane and later reviews point to trial-quality limits, missing eligible placebo-controlled MCI trials at earlier search dates, and results that should not be generalized to healthy users.

Phase II trial context1
In a multicenter phase II trial, 200 mcg twice daily did not show the planned cognitive benefit at 16 weeks. A higher 400 mcg twice-daily arm showed a secondary signal, but global, daily-living, and neuropsychiatric outcomes were not clearly improved.
Review context5
A 2013 meta-analysis reported favorable results in Alzheimer's disease trials but cautioned that most trials had high risk of bias. A 2019 MCI meta-analysis reported favorable scale changes while also noting low original-study quality and the need for better trials.
02

Names, aliases and forms

Common NameHuperzine A
AbbreviationHupA
Scientific NameHuperzia serrata
Taxonomic SynonymLycopodium serratum
Active ConstituentAcetylcholinesterase inhibitor
Standardized Extract1% huperzine A
03

Mechanisms of action

Mechanism to understand

1

Huperzine A inhibits acetylcholinesterase, the enzyme that breaks down acetylcholine. That mechanism explains why it is discussed for cognition, but it also explains the interaction and side-effect caution.

04

Potential effects and evidence map

Grade C overall: Huperzine A has human cognitive research in clinical impairment populations and a verified cholinergic mechanism, but findings are mixed, population-specific, and not a clean healthy-user focus or productivity signal.

Effect domainMagnitudeGrade
Memory / learning5
CumulativeConfidence: Medium

Has clinical-context signals on cognitive scales in Alzheimer's disease and MCI literature, but this does not establish healthy-adult memory enhancement.

Note Keep impairment-population evidence separate from consumer nootropic claims.

2/5
C
Focus / attention1
UnknownConfidence: Low

Healthy-user focus and attention support is speculative; most support is mechanistic or extrapolated from clinical cognition research.

Note Avoid presenting Huperzine A as a proven productivity or study aid.

1/5
D
Mental energy / wakefulness2
UnknownConfidence: Low

It is not a stimulant and should not be framed as reliable mental energy or wakefulness support.

Note Cholinergic side effects can feel activating or uncomfortable without implying useful energy.

0/5
D
05

Typical dosages and timing

Typical
300-500 mcg/day
Not a recommendation
Lower bound
300 mcg/day
Profile value
Upper bound
500 mcg/day
Profile value
Alzheimer disease trials8300-500 mcg/day

An older meta-analysis of four Alzheimer disease trials reported 300-500 mcg/day for 8-24 weeks. Those trial regimens were studied in a clinical population and do not establish a consumer-label dose or a healthy-user dosing recommendation.

06

Timing & effect horizon

Effect horizonUnknown
Unknown
Half-life2Acute
12 hours
Pharmacokinetic context2

A single 0.4 mg oral-dose study in healthy volunteers reported plasma appearance within minutes, peak concentration at about 58 minutes, and a beta The time for blood levels to fall by half during the final elimination phase.Source of about 716 minutes. These are pharmacokinetic values, not validated acute cognition timing claims.

07

Safety, side effects and risk profile

Potency and combination caution9
For generally healthy adults, available clinical evidence does not justify a high intrinsic risk rating. The important caution is combination-specific: FDA draft guidance discusses potential effects when a cholinesterase-inhibiting ingredient such as huperzine A is combined with a cholinergic agonist.
Population evidence gaps9
The cited human studies do not establish safety or dosing for pregnancy, lactation, adolescents, or people with complex medication regimens. This lack of direct evidence should not be read as a quantified risk estimate.
Interaction risk9
Confidence: Medium

Combination-specific caution: FDA discusses potential effects when a cholinesterase-inhibiting ingredient such as huperzine A is combined with a cholinergic agonist.

Note This is not evidence for a universal medication-interaction list.

3/5
C
Cardiovascular caution9
Confidence: Low

Low heart rate or blood pressure are combination-specific concerns in FDA draft guidance for cholinesterase-inhibiting ingredients combined with a cholinergic agonist.

Note Do not generalize this scenario to a quantified intrinsic risk for all healthy users.

2/5
C
GI discomfort8
Confidence: Medium

Clinical Alzheimer disease trials reported mostly cholinergic adverse effects; relevance to healthy users is uncertain.

Note Clinical-context safety evidence should not be overgeneralized.

2/5
C
Headache / dizziness8
Confidence: Low

Headache and dizziness need cautious interpretation because healthy-user safety data are limited.

Note Do not infer frequency, severity, or causality beyond the cited clinical literature.

1/5
C
Overstimulation / insomnia8
Confidence: Low

Sleep effects are not well characterized by the cited human studies.

Note An evidence gap is not a quantified risk estimate.

1/5
E
Pregnancy / lactation caution9
Confidence: Low

The cited human studies do not establish pregnancy or lactation safety.

Note Absence of direct evidence is a limitation, not a quantified risk estimate.

2/5
E
Evidence uncertainty5
Confidence: High

Most human evidence is from clinical impairment populations with trial-quality limitations, so it does not establish healthy-user benefit.

Note Keep clinical-context findings separate from healthy-adult nootropic claims.

2/5
B
Reported pattern8Mostly cholinergic adverse effects

In four Alzheimer disease trials summarized in a 2009 meta-analysis, most reported adverse effects were cholinergic and no serious adverse events were reported. These findings do not quantify safety for healthy users or every product form.

08

Interactions and cautions

Combination-specific evidence9

FDA draft guidance names huperzine A as an example of a cholinesterase-inhibiting ingredient for which combining with a cholinergic agonist may contribute to gastrointestinal distress, low blood pressure, low heart rate, or irregular heartbeat. The guidance does not establish a comprehensive medicine or supplement interaction list.

09

Legal and regulatory status

United States7

United States context (as of 2026): FDA does not approve dietary supplements for safety or effectiveness before marketing. This general regulatory framework does not determine the status, quality, or legality of any individual Huperzine A product.

10

How it compares

Huperzine A1

Compared with CDP-choline, alpha-GPC, or citicoline-style products, Huperzine A does not supply choline. It slows acetylcholine breakdown, which changes both the expected benefit profile and the interaction risk.

11

Practical buying and quality notes

  • Compare offers by stated active Huperzine A amount, form, and batch-level assay evidence; do not use raw powder weight as an active-dose proxy.1
  • A 1% powder contains about 10 mg huperzine A per gram of powder. Compare the labeled active amount and assay documentation; raw powder weight alone is not a reliable active-dose comparison.1
  • Prefer products that state huperzine A amount per serving in mcg, extract percentage, botanical or synthetic source where relevant, batch assay, contaminants testing, expiration date, and clear capsule count or powder weight.1
  • For Huperzine A, the first filter is not the lowest price. Check whether the product is a capsule or powder, whether the active amount is clearly stated in mcg, whether a COA verifies the assay, and whether the dose can be measured accurately.1
12

References

  1. Rafii MS, Walsh S, Little JT, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 2011.
  2. Li YX, Zhang RQ, Li CR, Jiang XH. Pharmacokinetics of huperzine A following oral administration to human volunteers. Eur J Drug Metab Pharmacokinet. 2007.
  3. Li J, Wu HM, Zhou RL, Liu GJ, Dong BR. Huperzine A for Alzheimer's disease. Cochrane Database Syst Rev. 2008.
  4. Yue J, Dong BR, Lin X, Yang M, Wu HM, Wu T. Huperzine A for mild cognitive impairment. Cochrane Database Syst Rev. 2012.
  5. Yang G, Wang Y, Tian J, Liu JP. Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. PLoS One. 2013.
  6. Huang P, Li B, Guo YH, Feng S, Hu J, Liu QQ, et al. Efficacy and safety of huperzine A in mild cognitive impairment: systematic review and meta-analysis. Zhongguo Zhong Yao Za Zhi. 2019.
  7. U.S. FDA. Information for Consumers on Using Dietary Supplements.
  8. Wang BS, Wang H, Wei ZH, et al. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis. J Neural Transm. 2009.
  9. U.S. Food and Drug Administration. Revised Draft Guidance for Industry: Dietary Supplements: New Dietary Ingredient Notifications and Related Issues. 2024.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.